Paolo Maria Comoglio
Overview
Explore the profile of Paolo Maria Comoglio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
941
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Crepaldi T, Gallo S, Comoglio P
Pharmaceuticals (Basel)
. 2024 Apr;
17(4).
PMID: 38675409
The discovery and subsequent research on the MET oncogene's role in cancer onset and progression have illuminated crucial insights into the molecular mechanisms driving malignancy. The identification of MET as...
2.
Gallo S, Vitacolonna A, Comoglio P, Crepaldi T
Cells
. 2024 Jan;
13(1).
PMID: 38201232
The involvement of the N-methyl-D-aspartate receptor (NMDAR), a glutamate-gated ion channel, in promoting the invasive growth of cancer cells is an area of ongoing investigation. Our previous findings revealed a...
3.
Altintas D, Gallo S, Basilico C, Cerqua M, Bocedi A, Vitacolonna A, et al.
Int J Mol Sci
. 2022 Oct;
23(20).
PMID: 36293286
The tyrosine kinase receptor encoded by the MET oncogene has been extensively studied. Surprisingly, one extracellular domain, PSI, evolutionary conserved between plexins, semaphorins, and integrins, has no established function. The...
4.
Chiriaco C, Donini C, Cortese M, Ughetto S, Modica C, Martinelli I, et al.
J Exp Clin Cancer Res
. 2022 Oct;
41(1):309.
PMID: 36271379
Background: Aberrant activation of the MET receptor in cancer is sustained by genetic alterations or, more frequently, by transcriptional upregulations. A fraction of MET-amplified or mutated tumors are sensible to...
5.
Desole C, Gallo S, Vitacolonna A, Vigna E, Basilico C, Montarolo F, et al.
Front Immunol
. 2021 Dec;
12:775151.
PMID: 34925346
The Hepatocyte growth factor (HGF) and its receptor (MET) promote several physiological activities such as tissue regeneration and protection from cell injury of epithelial, endothelial, neuronal and muscle cells. The...
6.
Gallo S, Spilinga M, Casanova E, Bonzano A, Boccaccio C, Comoglio P, et al.
Int J Mol Sci
. 2020 Jul;
21(15).
PMID: 32722178
Previous studies showed that the hepatocyte growth factor (HGF)-Met receptor axis plays long-lasting cardioprotection against doxorubicin anti-cancer therapy. Here, we explored the mechanism(s) underlying the HGF protective effect. DNA damage...
7.
Modica C, Gallo S, Chiriaco C, Spilinga M, Comoglio P, Crepaldi T, et al.
Cancers (Basel)
. 2020 Apr;
12(3).
PMID: 32245152
The oncogene encodes a tyrosine kinase receptor involved in the control of a complex network of biological responses that include protection from apoptosis and stimulation of cell growth during embryogenesis,...
8.
Gallo S, Spilinga M, Albano R, Ferrauto G, Di Gregorio E, Casanova E, et al.
Br J Pharmacol
. 2020 Mar;
177(13):3107-3122.
PMID: 32133617
Background And Purpose: Doxorubicin anti-cancer therapy is associated with cardiotoxicity, resulting from DNA damage response (DDR). Hepatocyte growth factor (HGF) protects cardiomyocytes from injury, but its effective use is compromised...
9.
Apicella M, Giannoni E, Fiore S, Ferrari K, Fernandez-Perez D, Isella C, et al.
Cell Metab
. 2018 Sep;
28(6):848-865.e6.
PMID: 30174307
The microenvironment influences cancer drug response and sustains resistance to therapies targeting receptor-tyrosine kinases. However, if and how the tumor microenvironment can be altered during treatment, contributing to resistance onset,...
10.
Milan M, Benvenuti S, Balderacchi A, Virzi A, Gentile A, Senetta R, et al.
ERJ Open Res
. 2018 Mar;
4(1).
PMID: 29531956
http://ow.ly/RTUp30hSBX6.